![]() Moderna said it had shared the new finding on its vaccine with regulators and submitted it for peer review publication. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the updated shots. The CDC has previously indicated that BA.2.86 may be more capable of causing infection in people who previously had COVID or were vaccinated with previous shots. "This was not an anticipated catalyst that people were waiting for," he said, adding that Moderna continues to be a favorite target of Wall Street short sellers who bet that shares will fall. Both the Moderna and Pfizer/BioNTech shots are based on mRNA technology. TD Cowen analyst Tyler Van Buren said Wednesday's news was unlikely to raise the share price because people already assume the mRNA vaccines will continue to be effective against new COVID variants as they crop up. Moderna shares were down 1.6% and Pfizer shares were off nearly 3% in afternoon trading. ![]() Those are expected to be rolled out this autumn. Moderna, Pfizer/BioNTech and relative newcomer to the COVID vaccine market Novavax have created versions of their shots aimed at the XBB.1.5 subvariant, the dominant variant through most of 2023. Pfizer said its updated vaccine with partner BioNTech elicited a strong antibody response against BA.2.86 in a preclinical study in mice. “We think this is news people will want to hear as they prepare to go out and get their fall boosters,” Moderna head of infectious diseases Jacqueline Miller said in an interview, adding that the data should also help reassure regulators. Centers for Disease Control and Prevention (CDC). The variant is currently being tracked by the World Health Organization (WHO) and the U.S. Moderna said its shot generated an 8.7-fold increase in neutralizing antibodies against BA.2.86 compared with an untreated natural antibody response in clinical trials in humans. (Reuters) -Moderna and rival Pfizer on Wednesday said their updated COVID-19 vaccines generated strong responses in testing against the highly mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |